Private Equity Profile
In the last 3 years, Ampersand Capital Partners has acquired 7 companies. It has also invested in 11 others.
Ampersand Capital Partners’ most common sectors for investment are life science (48%) and medical products (26%). The Firm’s most common investment types include buyout (lbo, mbo, mbi) (33%) and growth capital (31%). In total, Ampersand Capital Partners has invested in 20 US states and 6 different countries. Its largest (disclosed) acquisition occurred in 2013 when it acquired BioClinica for $123M.
In the last 3 years, Ampersand Capital Partners has exited 10 companies. The Firm’s most common exit type is trade sale (73%). Ampersand Capital Partners’ largest (disclosed) exit occurred in 2008 when it sold Talecris Biotherapeutics Holdings Corp for $3.1B.
Join Mergr to view Ampersand Capital Partners’ full profile and discover more large private equity firms just like it.
M&A Total Activity102
- M&A Buy Activity59
- M&A Sell Activity43
- Total Sectors Invested 12
- Total Countries Invested 6
- M&A Buy/Sell Connections 53
- M&A Advisors 1